Subsequent screening of a larger cohort, 649 European American BC cases from TCGA, identified numerous rare, non-synonymous variants in HCAR1, HCAR2, and HCAR3, but only variants in HCAR2 were associated with BC risk. This evidence concerns the gene HCAR3 and breast cancer.